© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
This Year in Primary Care: 10 Critical Updates in 2025
December 23, 2025
Stay informed with the latest critical updates, including new guidelines, vaccine insights, and groundbreaking research findings from 2025.
FDA Approves First Oral GLP-1 Receptor Agonist for Chronic Weight Management
December 23, 2025
The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.
FDA Approves Abbott Volt Pulsed Field Ablation System for Treatment of Atrial Fibrillation
December 22, 2025
Abbott's Volt PFA System gains FDA approval, offering a new minimally invasive treatment for atrial fibrillation, enhancing patient care options.
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
December 19, 2025
Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.
Colonoscopy May be the Gold Standard, But Now It's a CRC Screening Bottleneck, Says Mark Fendrick, MD
December 19, 2025
Completion of the screening pathway—not test selection alone—may define quality going forward.
When Daily Oral PrEP Is Not the Best Fit: Lessons From Clinical Practice
December 19, 2025
Real-world patient cases illustrating how pill burden, privacy, and individual preferences influence PrEP selection and adherence.
Moderate-to-Severe OSA Tied to Doubled Risk of Brain Microbleeds: Daily Dose
December 19, 2025
Your daily dose of the clinical news you may have missed.
Tezepelumab Achieves Dual Benefit in Adults with Severe Asthma: Daily Dose
December 18, 2025
Your daily dose of the clinical news you may have missed.
FDA Approves Lerodalcibep, Third-Generation PCSK9 Inhibitor, to Treat Hypercholesterolemia, Including HeFH
December 18, 2025
Phase 3 LIBerate data showed sustained LDL-C reductions of 60% or more in high-risk patients and 50% or more in HeFH, with once-monthly self-administration.
How Long-Acting Injectable PrEP Reshapes the Patient–Provider Relationship
December 18, 2025
Primary care physician Kevin Hatfield, MD, discusses how the switch can increase patient touchpoints, free cognitive burden, and strengthen long-term engagement between patients and PCPs.